Product Information for the Patient
Abiraterone Mylan 500 mg Film-Coated Tablets
Abiraterone Mylan 1.000 mg Film-Coated Tablets
abiraterone acetate
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
Abiraterona Mylan contains a medicine called abiraterone acetate. It is used for the treatment of prostate cancer in adult men whose cancer has spread to other parts of the body. Abiraterona Mylan makes your body stop producing testosterone; in this way it can delay the growth of prostate cancer.
When Abiraterona Mylan is prescribed in the initial stages of the disease and there is still a response to hormonal treatment, it is used together with a treatment to reduce testosterone (androgen deprivation treatment).
When you take this medicine, your doctor will prescribe another medicine called prednisone or prednisolone, to reduce the possibility of suffering an increase in blood pressure, accumulating too much fluid in your body (fluid retention) or decreasing the levels of a chemical called potassium in your blood.
Do not take Abiraterona Mylan
Do not take this medicine if any of the above applies to you. If you are unsure, consult your doctor or pharmacist before taking this medicine.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medicine:
Inform your doctor if you have been told that you have any heart or blood vessel problems, including heart rhythm problems (arrhythmia), or are being treated with medicines for these conditions.
Inform your doctor if you have yellowing of the skin or eyes, dark urine, or severe nausea or vomiting, as these may be signs or symptoms of liver problems. Rarely, acute liver failure may occur, which can be fatal.
You may experience a decrease in the number of red blood cells in the blood, reduced libido, and cases of muscle weakness and/or muscle pain.
Abiraterona Mylan should not be administered in combination with Ra-223 due to a possible increased risk of bone fracture or death.
If you plan to take Ra-223 after treatment with Abiraterona Mylan and prednisone/prednisolone, you should wait 5 days before starting the treatment with Ra-223.
If you are unsure if any of the above applies to you, consult your doctor or pharmacist before taking this medicine.
Blood tests
Abiraterona Mylan may affect your liver, even if you have no symptoms. While taking this medicine, your doctor will make periodic blood tests to monitor any effect on your liver.
Children and adolescents
This medicine should not be used in children or adolescents. If a child or adolescent accidentally ingests Abiraterona Mylan, they should immediately go to the hospital and bring the package insert with them to show to the emergency doctor.
Other medicines and Abiraterona Mylan
Consult your doctor or pharmacist before taking any other medicine.
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine. This is important because Abiraterona Mylan may increase the effects of a range of medicines, including heart medicines, tranquilizers, some diabetes medicines, herbal medicines (e.g., St. John's Wort), and others. Your doctor may consider changing the dose of these medicines. Additionally, some medicines may increase or decrease the effects of Abiraterona Mylan, which may lead to side effects or Abiraterona Mylan not working as well as it should.
The androgen deprivation therapy may increase the risk of heart rhythm problems. Inform your doctor if you are being treated with medicines:
Consult with your doctor if you are taking any of the medicines listed above.
Taking Abiraterona Mylan with food
Pregnancy and breastfeeding
Abiraterona Mylan is not indicated in women.
Driving and operating machines
This medicine is unlikely to affect your ability to drive and use tools or machines.
Abiraterona Mylan contains lactose and sodium
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
How much to take
The recommended dose is 1,000 mg (two 500 mg tablets or one 1,000 mg tablet) once a day.
How to take this medication
You may also be prescribed other medications while taking Abiraterona Mylan and prednisone or prednisolone.
If you take more Abiraterona Mylan than you should
If you take more than you should, consult your doctor or go to the hospital immediately.
If you forget to take Abiraterona Mylan
If you interrupt treatment with Abiraterona Mylan
Do not stop taking Abiraterona Mylan or prednisone or prednisolone unless your doctor tells you to.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Stop taking Abiraterona Mylan and seek medical attention immediately if you experience any of the following side effects:
These may be signs of low potassium levels in your blood.
Other side effects are:
Very common(may affect more than 1 in 10 people):
Fluid retention in the legs or feet, low potassium levels in the blood, elevated liver function test results, high blood pressure, urinary tract infections, diarrhea.
Common(may affect up to 1 in 10 people):
High levels of fats in the blood, chest pain, irregular heartbeat (atrial fibrillation), heart failure, tachycardia, severe infections called sepsis, bone fractures, indigestion, blood in the urine, skin rash.
Uncommon(may affect up to 1 in 100 people):
Problems with the adrenal glands (related to issues with salt and water), abnormal heart rhythm (arrhythmia), muscle weakness and/or muscle pain.
Rare(may affect up to 1 in 1,000 people):
Pulmonary irritation (also known as allergic alveolitis).
Failure of liver function (also known as acute liver failure).
Frequency not known(cannot be estimated from available data):
Heart attack, changes in the electrocardiogram-ECG (prolongation of QT), and severe allergic reactions with difficulty swallowing or breathing, swollen face, lips, tongue, or throat, or itchy rash.
This medicine may cause bone density loss in men receiving treatment for prostate cancer. Abiraterona in combination with prednisone or prednisolone may increase this bone density loss.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a side effect not listed in this leaflet. You can also report them directly through thenational reporting system included in theAppendix V. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box, blister pack, and bottle after “CAD”. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This will help protect the environment.
Abiraterone Mylan Content
The active ingredient is abiraterone acetate. Each film-coated tablet contains 500 mg or 1,000 mg of abiraterone acetate.
The other components are:
Core tablet : sodium croscarmellose (E468), sodium lauryl sulfate, povidone, microcrystalline cellulose (E460), lactose monohydrate, anhydrous colloidal silica (E551), and magnesium stearate (E470b).
Film coating : polyvinyl alcohol, titanium dioxide (E171), macrogol (E1521), and talc (E553b). In addition, the 500 mg tablets contain iron oxide red (E172) and iron oxide black (E172).
See section 2 "Abiraterone Mylan contains lactose and sodium."
Appearance of the product and contents of the package
Abiraterone Mylan 500 mg film-coated tablets are brown, oval-shaped (19 mm in length x 10 mm in width), with "500" engraved on one side and are available in blister packs containing 56, 60 tablets, and in perforated blister packs containing 56 x 1, 60 x 1 tablets.
Abiraterone Mylan 1,000 mg film-coated tablets are white or almost white, oval-shaped (23 mm in length x 11 mm in width), with a groove on one side and a flat surface on the other side, available in bottles containing 28 or 30 tablets, and also available in blister packs containing 28 or 30 tablets, and in perforated blister packs containing 28 x 1 or 30 x 1 tablets. The bottle also contains an oxygen absorber. Do not ingest the oxygen absorber, as it may be harmful to your health.
Only some package sizes may be commercially available.
Marketing authorization holder
Mylan Ireland Limited
Unit 35/36 Grange Parade,
Baldoyle Industrial Estate
Dublin 13,
Ireland.
Responsible for manufacturing
Remedica Ltd.,
Aharnon Street,
Limassol Industrial Estate,
3056 Limassol,
Cyprus
For more information about this medicine, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien Mylan bvba/sprl Tél/Tel: + 32 (0)2 658 61 00 | Lietuva Mylan Healthcare UAB Tel: +370 5 205 1288 |
Luxembourg/Luxemburg Mylan bvba/sprl Tél/Tel: + 32 (0)2 658 61 00 (Belgique/Belgien) | Ceská republika Viatris CZ.s.r.o. Tel: + 420 222 004 400 |
Danmark Viatris ApS Tlf: +45 28 11 69 32 | Malta V.J. Salomone Pharma Ltd. Tel: + 356 21 22 01 74 |
Deutschland Viatris Healthcare GmbH Tel: +49 800 0700 800 | Nederland Mylan BV Tel: +31 (0)20 426 3300 |
Eesti BGP Products Switzerland GmbH Eesti filiaal Tel: + 372 6363 052 | Norge Viatris AS Tlf: + 47 66 75 33 00 |
Ελλάδα Generics Pharma Hellas ΕΠΕ Τηλ: +30 210 993 6410 | Österreich Arcana Arzneimittel GmbH Tel: +43 1 416 2418 |
España Viatris Pharmaceuticals, S.L.U. Tel: + 34 900 102 712 | Polska Mylan Healthcare Sp. z. o.o. Tel: + 48 22 546 64 00 |
France Viatris Santé Tél: +33 4 37 25 75 00 | Portugal Mylan, Lda. Tel: + 351 21 412 72 56 |
Hrvatska Mylan Hrvatska d.o.o. Tel: +385 1 23 50 599 | România BGP Products SRL Tel: +40 372 579 000 |
Ireland Mylan Ireland Limited Tel: +353 1 8711600 | Slovenija Mylan Healthcare d.o.o. Tel: + 386 1 23 63 180 |
Ísland Icepharma hf Sími: +354 540 8000 | Slovenská republika Viatris Slovakia s.r.o. Tel: +421 2 32 199 100 |
Italia Mylan Italia S.r.l. Tel: + 39 02 612 46921 | Suomi/Finland Viatris Oy Puh/Tel: +358 20 720 9555 |
Κύπρος Varnavas Hadjipanayis Ltd. Τηλ: +357 2220 7700 | Sverige Viatris AB Tel: + 46 (0)8 630 19 00 |
Latvija Mylan Healthcare SIA Tel: +371 676 055 80 | United Kingdom (Northern Ireland) Mylan IRE Healthcare Limited Tel: +353 18711600 |
Last review date of this leaflet
Other sources of information
The detailed information on this medicine is available on the website of the European Medicines Agency: http://www.ema.europa.eu .
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.